08:44 AM EDT, 03/28/2024 (MT Newswires) -- Merck ( MRK ) said Thursday that the European Commission has approved Keytruda, in combination with platinum-containing chemotherapy as neoadjuvant treatment, to treat resectable non-small cell lung cancer.

The commission's approval was based on the company's phase 3 Keynote-671 trial, followed by the positive recommendation from the Committee for Medicinal Products for Human Use last month, Merck ( MRK ) added.

With this approval, the company receives marketing rights for Keytruda in all European Union states, as well as Iceland, Liechtenstein, Norway, and Northern Ireland, Merck ( MRK ) said.

Price: 132.6, Change: +0.85, Percent Change: +0.65